Development of fluorizoline analogues as prohibitin ligands that modulate C-RAF signaling, p21 expression and melanogenesis.


Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
15 Nov 2022
Historique:
received: 27 05 2022
revised: 25 07 2022
accepted: 25 07 2022
pubmed: 22 8 2022
medline: 21 9 2022
entrez: 21 8 2022
Statut: ppublish

Résumé

Fluorizoline is a cytotoxic trifluorothiazoline that targets the scaffold proteins prohibitins-1 and -2 (PHB1/2) to inhibit the kinase C-RAF and promote the expression of the cyclin-dependent kinase inhibitor p21 to induce cancer cell death. In melanocytes, fluorizoline also induces the synthesis of melanin. Herein we report the first structural requirement of fluorizoline analogues for these activities. We identified in particular some compounds that display enhanced anti-C-RAF and anti-MEK activities, and a higher cytotoxicity in HeLa cells compared to fluorizoline. These results provide a foundation for further optimization of PHB ligands for the treatment of cancers. We also discovered an analogue of fluorizoline that displays pharmacological effects opposed to those of fluorizoline and that can be used as a chemical tool to explore PHB signaling in cancers and other diseases.

Identifiants

pubmed: 35988448
pii: S0223-5234(22)00537-2
doi: 10.1016/j.ejmech.2022.114635
pii:
doi:

Substances chimiques

Cyclin-Dependent Kinase Inhibitor p21 0
Ligands 0
Melanins 0
Prohibitins 0
Proto-Oncogene Proteins 0
Repressor Proteins 0
Transcription Factors 0
Protein Serine-Threonine Kinases EC 2.7.11.1
Proto-Oncogene Proteins c-raf EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114635

Informations de copyright

Copyright © 2022. Published by Elsevier Masson SAS.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Nora Chouha (N)

Regenerative Nanomedicine (UMR 1260), INSERM, University of Strasbourg, Center of Research in Biomedicine of Strasbourg, 1 Rue Eugène Boeckel, 67000, Strasbourg, France; Laboratory of Chemistry and Environmental Chemistry (LCCE), Department of Chemistry, Faculty of Sciences, Batna-1 University, Batna, Algeria.

Hussein Abou-Hamdan (H)

Regenerative Nanomedicine (UMR 1260), INSERM, University of Strasbourg, Center of Research in Biomedicine of Strasbourg, 1 Rue Eugène Boeckel, 67000, Strasbourg, France.

Hajime Yurugi (H)

Cell Biology Unit, University Medical Center Mainz, JGU-Mainz, Germany.

Riku Yoshii (R)

Department of Clinical Oncology, Kyoto Pharmaceutical University, Misasagi-Nakauchicho 5, Yamashinaku, Kyoto, 607-8414, Japan.

Hiromi Ii (H)

Department of Clinical Oncology, Kyoto Pharmaceutical University, Misasagi-Nakauchicho 5, Yamashinaku, Kyoto, 607-8414, Japan.

Ahmad Najem (A)

Laboratory of Oncology and Experimental Surgery (LOCE), Institut Jules Bordet, Université Libre de Bruxelles, 1070, Anderlecht, Belgium.

Ghanem E Ghanem (GE)

Laboratory of Oncology and Experimental Surgery (LOCE), Institut Jules Bordet, Université Libre de Bruxelles, 1070, Anderlecht, Belgium.

Susumu Nakata (S)

Department of Clinical Oncology, Kyoto Pharmaceutical University, Misasagi-Nakauchicho 5, Yamashinaku, Kyoto, 607-8414, Japan.

Krishnaraj Rajalingam (K)

Cell Biology Unit, University Medical Center Mainz, JGU-Mainz, Germany.

Yu Peng (Y)

Sino-French Joint Lab of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China.

Dong Wang (D)

Institute of Materia Medica, Xinjiang University, Urumqi, 830017, Xinjiang, China.

Canan G Nebigil (CG)

Regenerative Nanomedicine (UMR 1260), INSERM, University of Strasbourg, Center of Research in Biomedicine of Strasbourg, 1 Rue Eugène Boeckel, 67000, Strasbourg, France.

Laurent Désaubry (L)

Regenerative Nanomedicine (UMR 1260), INSERM, University of Strasbourg, Center of Research in Biomedicine of Strasbourg, 1 Rue Eugène Boeckel, 67000, Strasbourg, France; Sino-French Joint Lab of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China. Electronic address: desaubry@unistra.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH